Covestor’s Capricor Therapeutics CAPR Stock Holding History

Covestor’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Buy	19 +14	+280%	+$424	﹤0.01%	2504
2026 Q1	$0	Buy	+5	New	+$133	﹤0.01%	2290

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Covestor's CAPR Position: Q2 2026 in Review

Covestor increased its Capricor Therapeutics (CAPR) stake by 280% in Q2 2026, buying an estimated $424 and bringing the position to 19 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2504.

Covestor first reported a position in CAPR in Q1 2026 and has held it in 2 quarters since. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

Covestor held 19 shares of Capricor Therapeutics worth $0 as of Q2 2026.
Covestor bought 14 Capricor Therapeutics shares in Q2 2026, an estimated $424.
Capricor Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2504 holding.
Covestor first reported a position in Capricor Therapeutics in Q1 2026 and has held it in 2 quarters since.
169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.